Avalyn Pharma Highlighting Inhalation Platform at Upcoming H.C. Wainwright and Hanson Wade Conferences in June
June 15, 2023 – SEATTLE — Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases, announced that CFO Marc Schneebaum will present at the H.C. Wainwright 2nd Annual Private Company Showcase, which is taking place June 20-22, 2023 on Kiawah Island, SC. Mr. Schneebaum will provide a corporate and clinical update and will discuss Avalyn’s targeted approach to treating severe and rare lung diseases with inhaled therapeutics.
To further expand on the company’s strategy of delivering pulmonary medicines directly to the lungs via inhalation technology, Stephen Pham, Ph.D., Avalyn’s senior vice president of product development will participate in the Hanson & Wade Next Gen Inhalation Delivery Summit being held June 20-22, 2023 in Boston, MA. Dr. Pham will act as chairman on Day 3 with a keynote introducing the proceedings, which are focused on methods of enhancing formulations of inhaled medicines to increase stability, improve drug-device compatibility, and optimize efficacy. On that day, he will make an oral presentation on the company’s product development experience and rationale for selecting PARI’s eFlow® Technology Nebulizer, a high efficiency vibrating membrane nebulizer used by Avalyn to deliver AP01 (inhaled pirfenidone) in its clinical trials and is currently in use in Avalyn’s AP01-005 open label extension study in patients with pulmonary fibrosis. In addition, Dr. Pham will lead an expert panel discussion on the factors that inform the selection of an inhaler platform, be it a metered-dose inhaler, dry powder inhaler, or nebulizer, based on the disease, patient population and drug characteristics.
H.C. Wainwright 2nd Annual Private Company Showcase
Date/Time: June 21, 2023 and 10:00 a.m. Eastern Time
Location: The Sanctuary at Kiawah Island
Next Gen Inhalation Delivery Summit
Oral Presentation: Selection of an Aerosol Delivery System for an Inhalation Product
Date/Time: June 22, 2023 and 12:00 p.m. Eastern Time
Location: The Bostonian
Roundtable Discussion: Addressing Key Questions of Formulating in Dry Powder Inhalers (DPI) vs Liquid / Nebulizers vs Metered Dose Inhalers (MDIs)
Date/Time: June 22, 2023 and 3:30 p.m. Eastern Time
Location: The Bostonian
About Avalyn Pharma
Avalyn is a biopharmaceutical company developing targeted therapeutics for the treatment of rare respiratory diseases including idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD). ILDs are characterized by scarring, decline in lung function, reduced exercise capacity and quality of life, and are associated with increased mortality. Currently approved therapeutic options slow ILD progression but are associated with significant toxicities, which restrict their use and dosing. Avalyn is developing a pipeline of inhaled therapeutics designed to reduce systemic exposure and deliver medication to the site of disease. AP01, Avalyn’s lead candidate, is an inhaled formulation of pirfenidone optimized for delivery via inhalation. In a recent clinical study of two doses assessed in 91 individuals with IPF, AP01 demonstrated the potential to improve both efficacy and safety over existing therapy. More information can be found at www.avalynpharma.com.